Metformin is the most heavily prescribed type 2 diabetes (T2D) drug and dominates the early lines of therapy before disease progression requires insulin replacement. The emergence of more-effective, safer, and better-tolerated therapies, such as sodium-glucose cotransporter-2 (SGLT– 2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonists, has provided physicians with a broad array of therapeutic options. Moreover, with a better understanding of T2D and its complications, individualization of treatment is becoming more common. Numerous branded agents from both established and recently launched classes are now jostling for position in the treatment paradigm.
Markets covered: United States
Key companies: Eli Lilly, Merck, Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Pfizer, Sanofi
Key drugs: Apidra, Basaglar, Humalog, Januvia, Jardiance, Lantus, Levemir, metformin, Mounjaro, Novolog, Ozempic, Rybelsus, Steglatro, Toujeo, Tresiba, Trulicity, Victoza
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.